Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

The elevated methionine (MET) use by cancer cells is termed MET dependence and may be the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo. We previously reported that rMETase, administrated...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Cycle
Main Authors: Kawaguchi, Kei, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Kiyuna, Tasuku, Miyake, Kentaro, Miyake, Masuyo, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Singh, Arun S., Eckardt, Mark A., Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2018
Assuntos:
Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914727/
https://ncbi.nlm.nih.gov/pubmed/29187018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1405195
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares